735262-21-2 Usage
Uses
Used in Pharmaceutical Industry:
PIPERIDINE-3-CARBOXYLIC ACID (4-METHOXY-PHENYL)-AMIDE is used as a chemical intermediate for the development of new drugs due to its potential pharmacological activities. Its unique structure and properties may contribute to the creation of innovative therapeutic agents.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, PIPERIDINE-3-CARBOXYLIC ACID (4-METHOXY-PHENYL)-AMIDE serves as a valuable compound for studying its interactions with biological targets and understanding its mechanism of action. This knowledge can aid in the design and optimization of more effective drug candidates.
Used in Drug Discovery and Development:
PIPERIDINE-3-CARBOXYLIC ACID (4-METHOXY-PHENYL)-AMIDE is utilized in drug discovery and development processes to identify and optimize potential drug candidates. Its unique chemical properties and pharmacological activities make it a valuable tool for exploring new therapeutic approaches and treatments for various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 735262-21-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,3,5,2,6 and 2 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 735262-21:
(8*7)+(7*3)+(6*5)+(5*2)+(4*6)+(3*2)+(2*2)+(1*1)=152
152 % 10 = 2
So 735262-21-2 is a valid CAS Registry Number.
735262-21-2Relevant articles and documents
Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles
Dong, Xiao-Wu,Zhang, Jian-Kang,Xu, Lei,Che, Jin-Xin,Cheng, Gang,Hu, Xiao-Bei,Sheng, Li,Gao, An-Hui,Li, Jia,Liu, Tao,Hu, Yong-Zhou,Zhou, Yu-Bo
supporting information, p. 602 - 614 (2019/01/11)
The potential of specific proteasome inhibitors to act as anti-cancer agents has attracted intensive investigations. The proteasome can be covalently inhibited by epoxyketone derivatives via a two-step reaction. Several computational approaches have been developed to mimic the covalent binding event. Compound 1 composed of a six-membered heterocyclic ring was designed by using covalent docking. With a possible different binding mode from the clinical compound Carfilzomib, it occupied the S5 pocket of 20S proteasome and showed favorable inhibitory activity. Subsequently optimization and evaluation were taken place. Among these compounds, 11h demonstrated extraordinary in vitro inhibitory activity and selectivity, and good in vivo proteasome inhibitory activity, a favorable pharmacokinetic profile and xenograft tumor inhibition. The possible binding pattern of compound 11h against proteasome was further fully explored via calculations, providing a theoretical basis for finding potent proteasome inhibitors.
